De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a complete overview and 2016 replace. Blood Most cancers J 2016;6:e441.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Most cancers statistics, 2022. CA: A Most cancers J Clin. 2022;72:7–33.
Hornick NI, Doron B, Abdelhamed S, Huan J, Harrington CA, Shen R, et al. AML suppresses hematopoiesis by releasing exosomes that comprise microRNAs concentrating on c-MYB. Sci Sign. 2016;9:ra88.
Abdelhamed S, Butler JT, Doron B, Halse A, Nemecek E, Wilmarth PA, et al. Extracellular vesicles impose quiescence on residual hematopoietic stem cells within the leukemic area of interest. EMBO Rep. 2019;20:e47546.
Binder S, Luciano M, Horejs-Hoeck J. The cytokine community in acute myeloid leukemia (AML): A concentrate on pro- and anti inflammatory mediators. Cytokine Progress Issue Rev. 2018;43:8–15.
Kristinsson SY, Björkholm M, Hultcrantz M, Derolf ÅR, Landgren O, Goldin LR. Persistent immune stimulation would possibly act as a set off for the event of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29:2897–903.
Pietras EM. Irritation: a key regulator of hematopoietic stem cell destiny in well being and illness. Blood .2017;130:1693–8.
Schepers Ok, Campbell TB, Passegué E. Regular and leukemic stem cell niches: insights and therapeutic alternatives. Cell Stem Cell. 2015;16:254–67.
Zhang TY, Dutta R, Benard B, Zhao F, Yin R, Majeti R. IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia. Sci Transl Med. 2020;12:eaax5104.
Zhao JL, Ma C, O’Connell MR, Mehta A, DiLoreto R, Heath JR, et al. Conversion of hazard alerts into cytokine alerts by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell. 2014;14:445–59.
Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, J Am Soc Hematol 2001;98:2301–7.
Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, et al. Identification of Interleukin-1 by Purposeful Screening as a Key Mediator of Mobile Growth and Illness Development in Acute Myeloid Leukemia. Cell Rep. 2017;18:3204–18.
Zambetti NA, Ping Z, Chen S, Kenswil KJ, Mylona MA, Sanders MA, et al. Mesenchymal irritation drives genotoxic stress in hematopoietic stem cells and predicts illness evolution in human pre-leukemia. Cell Stem Cell. 2016;19:613–27.
Essers MAG, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNα prompts dormant haematopoietic stem cells in vivo. Nature .2009;458:904.
Butler JT, Abdelhamed S, Kurre P. Extracellular vesicles within the hematopoietic microenvironment. Haematologica .2018;103:382–94.
Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, et al. An interferon-driven oxysterol-based protection towards tumor-derived extracellular vesicles. Most cancers Cell 2019;35:33–45. e6.
Kumar B, Garcia M, Weng L, Jung X, Murakami JL, Hu X, et al. Acute myeloid leukemia transforms the bone marrow area of interest right into a leukemia-permissive microenvironment by means of exosome secretion. Leukemia .2018;32:575–87.
Doron B, Abdelhamed S, Butler JT, Hashmi SK, Horton TM, Kurre P. Transmissible ER stress reconfigures the AML bone marrow compartment. Leukemia. 2019;33:918–30.
Pietras EM, Lakshminarasimhan R, Techner J-M, Fong S, Flach J, Binnewies M, et al. Re-entry into quiescence protects hematopoietic stem cells from the killing impact of persistent publicity to sort I interferons. J Exp Med. 2014;211:245–62.
Ju J-M, Jung MH, Nam G, Kim W, Oh S, Kim HD, et al. Escape from thymic deletion and anti-leukemic results of T cells particular for hematopoietic cell-restricted antigen. Nat Commun. 2018;9:225.
Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 2018;562:605–9.
Yan F, Shen N, Pang JX, Zhang YW, Rao EY, Bode AM, et al. Fatty acid-binding protein FABP4 mechanistically hyperlinks weight problems with aggressive AML by enhancing aberrant DNA methylation in AML cells. Leukemia .2017;31:1434–42.
Li J-M, Petersen CT, Li J-X, Panjwani R, Chandra DJ, Giver CR, et al. Modulation of immune checkpoints and graft-versus-leukemia in allogeneic transplants by antagonizing vasoactive intestinal peptide signaling. Most cancers Res. 2016;76:6802–15.
Curran E, Chen X, Corrales L, Kline DE, others. STING pathway activation stimulates potent immunity towards acute myeloid leukemia. Cell Rep. (2016).
Ratajczak M, Adamiak M, Deptala A, Domagala-Kulawik J, Ratajczak J, Kucia M. Myeloablative Conditioning for Transplantation Induces State of Sterile Irritation within the Bone Marrow: Implications for Optimizing Homing and Engraftment of Hematopoietic Stem Cells. Antioxidant & Redox Signaling. 2022;37:1254–65.
Pietras EM, Reynaud D, Kang Y-A, Carlin D, Calero-Nieto FJ, Leavitt AD, et al. Functionally distinct subsets of lineage-biased multipotent progenitors management blood manufacturing in regular and regenerative situations. Cell Stem Cell. 2015;17:35–46.
Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from dedicated progenitor to leukaemia stem cell initiated by MLL–AF9. Nature. 2006;442:818–22.
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia relies on aberrant H3K79 methylation by DOT1L. Most cancers Cell 2011;20:66–78.
Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, et al. MLL-AF9 expression in hematopoietic stem cells drives a extremely invasive AML expressing EMT-related genes linked to poor final result. Most cancers Cell. 2016;30:43–58.
Chen X, Burkhardt DB, Hartman AA, Hu X, Eastman AE, Solar C, et al. MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors. Nat Commun. 2019;10:5767.
Kelly-Scumpia KM, Scumpia PO, Delano MJ, Weinstein JS, Cuenca AG, Wynn JL, et al. Sort I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10. J Exp Med. 2010;207:319–26.
Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-γ in response to persistent an infection. Nature. 2010;465:793–7.
Kanayama M, Izumi Y, Yamauchi Y, Kuroda S, Shin T, Ishikawa S, et al. CD86-based evaluation permits statement of bona fide hematopoietic responses. Blood. 2020;136:1144–54.
Cai Z, Kotzin JJ, Ramdas B, Chen S, Nelanuthala S, Palam LR, et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell 2018;23:833–49.
Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H, et al. Therapy of persistent myelogenous leukemia by blocking cytokine alterations present in regular stem and progenitor cells. Most cancers Cell 2015;27:671–81.
Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK–STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic responseJAK–STAT pathway activation in malignant and nonmalignant cells in MPN. Most cancers Discov. 2015;5:316–31.
Holicek P, Truxova I, Rakova J, Salek C, Hensler M, Kovar M, et al. Sort I interferon signaling in malignant blasts contributes to therapy efficacy in AML sufferers. Cell Loss of life Dis. 2023;14:209.
de Laval B, Maurizio J, Kandalla P, Brisou G, Simonnet L, Huber C, et al. C/EBPβ-dependent epigenetic reminiscence induces skilled immunity in hematopoietic stem cells. Cell Stem Cell. 2020;26:657–74.
Abdelhamed S, Butler JT, Jung S, Chen D-W, Jenkins G, Gao L, et al. Rational biomarker improvement for the early and minimally invasive monitoring of AML. Blood Adv. 2021;5:4515–20.
Bogeska R, Mikecin A-M, Kaschutnig P, Fawaz M, Büchler-Schäff M, Le D, et al. Inflammatory publicity drives long-lived impairment of hematopoietic stem cell self-renewal exercise and accelerated getting older. Cell Stem Cell. 2022;29:1273–84.e8.
Schepers Ok, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow area of interest right into a self-reinforcing leukemic area of interest. Cell Stem Cell. 2013;13:285–99.
Miraki-Moud F, Anjos-Afonso F, Hodby KA, Griessinger E, Rosignoli G, Lillington D, et al. Acute myeloid leukemia doesn’t deplete regular hematopoietic stem cells however induces cytopenias by impeding their differentiation. Proc Natl Acad Sci. 2013;110:13576–81.
Boyd AL, Reid JC, Salci KR, Aslostovar L, Benoit YD, Shapovalova Z, et al. Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow area of interest. Nat Cell Biol. 2017;19:1336–47.
Akinduro O, Weber TS, Ang H, Haltalli M, Ruivo N, Duarte D, et al. Proliferation dynamics of acute myeloid leukaemia and haematopoietic progenitors competing for bone marrow house. Nat Commun. 2018;9:519.
Corces-Zimmerman MR, Hong W-J, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia have an effect on epigenetic regulators and persist in remission. Proc Natl Acad Sci. 2014;111:2548–53.
Caiado F, Pietras EM, Manz MG. Irritation as a regulator of hematopoietic stem cell operate in illness, getting older, and clonal choice. J Exp Med. 2021;218:e20201541.
Hormaechea-Agulla D, Matatall KA, Le DT, Kain B, Lengthy X, Kus P, et al. Persistent an infection drives Dnmt3a-loss-of-function clonal hematopoiesis through IFNγ signaling. Cell Stem Cell. 2021;28:1428–42.
Matatall KA, Jeong M, Chen S, Solar D, Chen F, Mo Q, et al. Persistent an infection depletes hematopoietic stem cells by means of stress-induced terminal differentiation. Cell Rep. 2016;17:2584–95.
Tall AR, Fuster JJ. Clonal hematopoiesis in heart problems and therapeutic implications. Nat Cardiovasc Res. 2022;1:116–24.
Gómez AM, Martínez C, González M, Luque A, Melen GJ, Martínez J, et al. Chemokines and relapses in childhood acute lymphoblastic leukemia: a job in migration and in resistance to antileukemic medicine. Blood Cells, Mol, Dis. 2015;55:220–7.
Lee Y, Chittezhath M, André V, Zhao H, Poidinger M, Biondi A, et al. Protumoral function of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. Blood, J Am Soc Hematol. 2012;119:227–37.
Sarris AH, Broxmeyer HE, Wirthmueller U, Karasavvas N, Cooper S, Lu L, et al. Human interferon-inducible protein 10: expression and purification of recombinant protein show inhibition of early human hematopoietic progenitors. J Exp Med. 1993;178:1127–32.
Aldinucci D, Poletto D, Nanni P, Degan M, Rupolo M, Pinto A, et al. CD40L induces proliferation, self-renewal, rescue from apoptosis, and manufacturing of cytokines by CD40-expressing AML blasts. Exp Hematol. 2002;30:1283–92.
Argiropoulos B, Palmqvist L, Yung E, Kuchenbauer F, Heuser M, Sly LM, et al. Linkage of Meis1 leukemogenic exercise to a number of downstream effectors together with Trib2 and Ccl3. Exp Hematol. 2008;36:845–59.
Kornblau SM, Mccue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are current and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood .2010;116:4251–61.
Vijay V, Miller R, Vue GS, Pezeshkian MB, Maywood M, Ast AM, et al. Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. Leuk Res. 2019;84:106180.
Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020;12:eaaz0463.
Stevens AM, Miller JM, Munoz JO, Gaikwad AS, Redell MS. Interleukin-6 ranges predict event-free survival in pediatric AML and recommend a mechanism of chemotherapy resistance. Blood Adv 2017;1:1387–97.
Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, et al. An inflammatory state remodels the immune microenvironment and improves danger stratification in acute myeloid leukemia. Nature Most cancers. 2022;4:27–42.
Bertoli S, Picard M, Bérard E, Griessinger E, Larrue C, Mouchel PL, et al. Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica. 2018;103:988–98.
